Luca Pignata

Luca Pignata

Auto-generated profile, based on publicly available information

Luca Pignata

Department of Clinical Medicine and Surgery, Gastroenterology and Hepatology Unit, University of Naples "Federico II", Naples, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Cancer Cell
Verified
Journal Article
Closed access
JFJia Yi Fong
Jia Yi Fong
LPLuca Pignata
Luca Pignata
PGPierre-Alexis Goy
Pierre-Alexis Goy
KKKimihito Cojin Kawabata
Kimihito Cojin Kawabata
SLStanley Lee
Stanley Lee
Ernesto GuccioneErnesto Guccione
Ernesto Guccione

1 May 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAkshay V. Bhat
Akshay V. Bhat
MKMonica Palanichamy Kala
Monica Palanichamy Kala
VRVinay Kumar Rao
Vinay Kumar Rao
LPLuca Pignata
Luca Pignata
HLHuey Jin Lim
Huey Jin Lim
RTReshma Taneja
Reshma Taneja
Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediatric cancer with poor prognosis. As transient and stable modifications to chromatin have emerged as critical mechanisms in oncogenic signaling, efforts to target epigenetic modifiers as a therapeutic strategy have accelerated in recent years. To identify chromatin modifiers that sustain tumor growth, we performed an epigenetic screen and found that inhibition of lysine methyltransferase G9a significantly affected the viability of ARMS cell lines. Targeting expression or activity of G9a reduced cellular proliferation and motility in vitro and tumor growth in vivo. Transcriptome and chromatin immunoprecipitation–sequencing analysis provided mechanistic evidence that the tumor-suppressor PTEN was a direct target gene of G9a. G9a repressed PTEN expression in a methyltransferase activity–dependent manner, resulting in increased AKT and RAC1 activity. Re-expression of constitutively active RAC1 in G9a-deficient tumor cells restored oncogenic phenotypes, demonstrating its critical functions downstream of G9a. Collectively, our study provides evidence for a G9a-dependent epigenetic program that regulates tumor growth and suggests targeting G9a as a therapeutic strategy in ARMS. Significance: These findings demonstrate that RAC1 is an effector of G9a oncogenic functions and highlight the potential of G9a inhibitors in the treatment of ARMS.

1 April 2015 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
MFMarco La Ferla
Marco La Ferla
AMAlberto Mercatanti
Alberto Mercatanti
GRGiulia Rocchi
Giulia Rocchi
SLSamuele Lodovichi
Samuele Lodovichi
TCTiziana Cervelli
Tiziana Cervelli
Alvaro GalliAlvaro Galli
Alvaro Galli

16 December 2022 in World Journal of Gastrointestinal Endoscopy
Verified
Journal Article
Open access
AMAlberto Martino
Alberto Martino
MSMarco Di Serafino
Marco Di Serafino
LALucio Amitrano
Lucio Amitrano
LOLuigi Orsini
Luigi Orsini
LPLorena Pietrini
Lorena Pietrini
GLGiovanni Lombardi
Giovanni Lombardi
Role of multidetector computed tomography angiography in non-variceal upper gastrointestinal bleeding: A comprehensive review

27 March 2026 in Science Advances
Verified
Journal Article
Open access
NPNesteene Joy Param
Nesteene Joy Param
EAElisa Arceci
Elisa Arceci
Francesco FiorentinoFrancesco Fiorentino
Francesco Fiorentino
LPLuca Pignata
Luca Pignata
DTDenis Torre
Denis Torre
Ernesto GuccioneErnesto Guccione
Ernesto Guccione
Acute myeloid leukemia (AML) is a hematopoietic malignancy caused by abnormal proliferation and differentiation of blasts. PRMT5, a methyltransferase that catalyzes symmetric dimethylation of arginine (SDMA) residues, has been implicated in cancer stem cell homeostasis and shown to be a potential therapeutic target in AML. However, given the toxicity of complete PRMT5 inhibition, there is a need to identify effective synergistic therapies. Through a targeted screen of compounds that inhibit key nodes of PRMT5-regulated pathways, we identified a synthetic lethality between inhibition of PRMT5 and LSD1, a lysine demethylase known to affect AML blast differentiation. The two inhibitors broadly reshape the transcriptome of targeted cells and synergize to promote AML differentiation and eventually growth inhibition and apoptosis, in a p53-dependent manner. To leverage this synthetic lethal interaction, we generated new dual compounds to inhibit both enzymes and recapitulated the effects of the drug combination. Our results uncover an unexpected convergence of PRMT5- and LSD1-regulated targets, paving the way for new therapeutic opportunities.

21 March 2022 in Digestive and Liver Disease
Verified
Journal Article
Closed access
VCValentina Cossiga
Valentina Cossiga
MAM.R. Attanasio
M.R. Attanasio
MCM. Capasso
M. Capasso
LPL. Pignata
L. Pignata
FCF.M. Cutolo
F.M. Cutolo
Filomena MoriscoFilomena Morisco
Filomena Morisco